Devices/Recall·FDA MedWatch Safety Alerts

Cryoprobe Recall: Erbe USA Removes Flexible Cryoprobes

HighPublished May 28, 2026· AI-analyzed May 28, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Erbe USA has initiated a recall of flexible cryoprobes due to a risk of the probes rupturing during activation.

Who it affects

This recall affects Erbe USA, healthcare facilities utilizing their flexible cryoprobes, and clinical teams responsible for interventional procedures using cryotechnology.

Why it matters

The potential for device rupture presents significant patient safety risks, including hearing loss, tinnitus, physical injury, or burns. From a regulatory perspective, this suggests a critical failure in device integrity or manufacturing quality control that warrants immediate mitigation and a thorough root cause analysis to prevent future malfunctions.

Practical takeaway

Regulatory and clinical teams should immediately identify and sequester affected flexible cryoprobes, conduct a risk assessment for patients recently treated with these devices, and ensure all field safety notices are documented for future FDA inspections.

FDA source material

Erbe Cryoprobes may rupture during activation, leading to potential hearing loss, tinnitus, injury, or burns.

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.